The Medicines Company (MDCO)

[akamaii]

Mdco gonna breakout to infinity and beyond

[DewDiligence]

The Court's decision on the Angiomax en banc hearing is due any day.

[DewDiligence]

$10.1M insider buy: #msg-122674290.

[DewDiligence]

MDCO divests Cleviprex and Kengreal for $260M cash up-front and $480M in contingent sales-based milestones:

http://finance.yahoo.com/news/medicines-company-agrees-divest-non-110000769.html

Note: MDCO has retained Angiomax.

[DewDiligence]

Musings on the Angiomax en banc hearing: #msg-122431465.

[SevenTenEleven]

MDCO - And completed today...

http://ih.advfn.com/p.php?pid=nmona&article=70200338

Good Luck!

[DewDiligence]

That deal was announced six week ago: #msg-119266127.

Tidying up for a buyout by Big Pharma is one possible explanation, but not the only explanation.

[SevenTenEleven]

MDCO - They sold their Hemostasis product portfolio today.

That product portfolio won't fit in the Big Pharma business model.

[DewDiligence]

That was last week's rumor. Why do you think it has validity?

[SevenTenEleven]

MDCO - Company is getting ready to be bought out. Big Pharma coming a calling, IMO.

The PCSK9 is likely the only thing of value.

[DewDiligence]

MDCO monetizes hemostatis portfolio: #msg-119266127.

[DewDiligence]

EGRX will launch liquid Angiomax product “at risk” as soon as it receives FDA approval:

#msg-118876127

Curious that MDCO never filed suit against EGRX under the standard Hatch-Waxman procedure.

[DewDiligence]

CAFC agrees to en banc rehearing of Angiomax patent case: #msg-118484166.

[akamaii]

Some one wanted 130k shares badly. Paid over ask I guess not easy shares around 38 gl

[akamaii]

Not really little bio correction today. That's all. Unless market crash this ones going higher

[SevenTenEleven]

MDCO - Back below $30 before anything above $40.

[DewDiligence]

The bear case for ALN-PCSsc: #msg-118426765.

[akamaii]

How's that handle working you're about to get the real test soon. Straight to 50 60 area soon

[smittypa]

Mea culpa on APB 700 potential. Did some research, and it looks like generic Propofol (by extrapolation) wholesales for about $17/vile, with annual sales, US & Euro combined, at close to $3 billion annually. I was assuming a much higher price, for ABP 700, than the market will bear. A $50/vile price, with superior efficacy, could possibly gain 33% of the 180 million annual anesthesia patients, or in the range of $3 billion annually. Obviously, the price will be negotiated with medicare/medicaid, and the likes of express scripts, so there is a great deal of potential variation, down the road.

[SevenTenEleven]

And that consensus is changing based upon recent data. Many going back to heparin as a base anticoagulant strategy. Better outcomes and significantly less stent thrombosis.

Facts is Facts buddy.

[DewDiligence]

Angiomax is no better than heparin.

Inasmuch as Angiomax had peak annual sales of a few hundred million dollars, there are obviously many who disagree with your assessment.

[SevenTenEleven]

They will spin it all out. Angiomax is no better than heparin. Not worth much moving forward regardless of the delivery mechanism.

Those shorting into the upside will capitalize on the proper DD...

[DewDiligence]

Cleviprex and Cangrelor (without Angiomax) don't amount to much, which is why I think MDCO might still have want to license EGRX's formulation of Angiomax.

It makes no difference to me whether the CV business gets spun out or stays with the parent company. Based on the CC, there are various reorganization options that are being considered.

[SevenTenEleven]

Per the conference call, they are planning on spinning out Angiomax, Clevidopine, and Cangrelor.

[DewDiligence]

Without a delineated future for Angiomax, MDCO wouldn't realize much in proceeds from selling the CV business. Hence the question about EGRX's product.

[SevenTenEleven]

MDCO - CV business to be sold off.

[DewDiligence]

Would love to see MDCO license the EGRX product, but with a very full plate, and most sales reps transitioned to new product, it doesn't seem probable…

If they still have cath-lab reps, what are they selling that is more lucrative than EGRX’s ready-to-use Angiomax?

Need to re-listen to the CC to verify what seemed almost ridiculous potential anesthesia patient numbers, Europe and US combined.

So do I.

[smittypa]

Would love to see MDCO license the EGRX product, but with a very full plate, and most sales reps transitioned to new product, it doesn't seem probable, at this point. IMO, ABP 700 has a potential (well over $15 billion per year, assuming phase 3 success) that outweighs almost any other early stage drug I can find. Need to relisten to the CC to verify what seemed almost ridiculous potential anesthesia patient numbers, Europe and US combined. MDCO 216 also has huge potential, but, the new trial involves a reformulation, so more risk than APCSK9. Carbavance will enter a crowded market, with strong competition, thus, IMO, less potential, than the other 3.

[DewDiligence]

p.s. Do you any chance that MDCO will license EGRX's ready-to-use formulation of Angiomax?

[DewDiligence]

Thanks for weighing in. Can you elaborate on why you rank the programs in that order?

[SevenTenEleven]

MDCO - Too bad I am not short, buddy...

Good Luck!

[smittypa]

Have to disagree, on MDCO's crown jewel. I would rank their four programs this way : [1] ABP 700 [2] APCSK9 [3] MDCO-216 [4] Carbavance. If I were to guess on the most likely spinco (in 6-18 months), it would be APCSK9 & MDCO-216 together. I suspect management will delay the spinoff as long as possible, to gather data that will enhance the IPO value.

[akamaii]

Looks like cup and handle type play these are very reliable. I would cover if I where you

[SevenTenEleven]

MDCO - Not really. More shorting into buying demand.

[akamaii]

Bud you got it wrong. Glty

[SevenTenEleven]

MDCO - Angiomax is a dying brand. No better than $0.05 worth of UFH. Why spend $1000's, when $0.05 will do?

[DewDiligence]

The PCSK9 program is clearly the crown jewel.

Regarding Angiomax, MDCO could continue to generate meaningful sales if it licensed EGRX's ready-to-use formulation.

[SevenTenEleven]

MDCO - Company is in deep debt now. Either break apart or be torn apart.

Revenue from Angiomax is slipping. Hard to keep the lights on when the main cash flow source continues to erode.

[DewDiligence]

MDCO discussing possible split-up on 3Q15 CC: #msg-118196795.

[SevenTenEleven]

MDCO - Play the bounce from $25! Earnings will disappoint once again.

Moving forward, earnings will play less and less into the PPS. Speculation on pipeline will be the only thing propping this up.

[akamaii]

From ta 30 worse case unless Dow collapses. Looks like it is starting to turn back up. I don't follow specifics on this one. I see some type of cup and handle here. Check out lf I think could be 2 in months. Gl thanks for sharing info

[SevenTenEleven]

Ah....I own!

Play the bounce!

[akamaii]

I follow this but no position I know you're short

[SevenTenEleven]

MDCO - $25/share coming after earnings.

Play the bounce.

[SevenTenEleven]

MDCO - Company will miss 3rd quarter earnings for the 3rd quarter in a row.

They will need to go to the market to raise capital, which means they will need to sell shares.

[akamaii]

Phase 3 very soon good stuff look into it it's called brialacidin unique moa

[SevenTenEleven]

MDCO - Investment in developing new antibiotics is very challenging. No one wants to pay for new therapies.

[akamaii]

No but have a unique antibiotic

[SevenTenEleven]

MDCO - Are they connected to MDCO?

[akamaii]

Check out ctix bud